electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

electroCore (Nasdaq: ECOR) announced that company management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.

Management will host one-on-one meetings throughout the day. Investors seeking a meeting should contact their Canaccord Genuity sales representative or email electroCore Investor Relations at ecor@fnkir.com.

News Market Reaction – ECOR

+1.29% 1.9x vol

1 alert

+1.29% Session close to close

$50.73M Market Cap

1.9x Rel. Volume

In the Nov 11 session, ECOR gained 1.29%, reflecting a mild positive market reaction. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.

Management will host one-on-one meetings throughout the day.

Investors who wish to request a meeting should contact their sales representative at Canaccord Genuity or reach out to electroCore Investor Relations at ecor@fnkir.com.

About electroCore, Inc.

electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell^® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact

ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

FAQ

When will electroCore (ECOR) participate at the Canaccord Genuity forum?

electroCore management will participate on Thursday, November 20, 2025.

Where is the Canaccord Genuity MedTech forum where ECOR will appear?

The forum takes place in New York at The Westin NY Grand Central Hotel.

How can investors request a one-on-one meeting with electroCore (ECOR) at the November 20, 2025 forum?

Investors should contact their Canaccord Genuity sales representative or email ecor@fnkir.com to request a meeting.

Will electroCore (ECOR) management hold multiple investor meetings at the event on November 20, 2025?

Yes. Management will host one-on-one meetings throughout the day.

Who should institutional investors contact to arrange meetings with ECOR at the Canaccord forum?

Institutional investors should contact their Canaccord Genuity sales representative or email ecor@fnkir.com.